Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial

Safety and efficacy of elsubrutinib or upadacitinib alone or in combination (ABBV-599) in patients with rheumatoid arthritis and inadequate response or intolerance to biological therapies: a multicentre, double-blind, randomised, controlled, phase 2 trial

Background ABBV-599 is a novel fixed-dose combination of the Bruton's tyrosine kinase (BTK) inhibitor elsubrutinib and the Janus kinase (JAK) inhibitor upadacitinib under investigation for the treatment of autoimmune diseases. We aimed to determine whether ABBV-599 could increase the treatment...

Descripció completa

Dades bibliogràfiques
Autors principals:	Fleischmann, R, Friedman, A, Drescher, E, Singhal, A, Cortes-Maisonet, G, Doan, T, Lu, W, Wang, Z, Nader, A, Housley, W, Cohen, S, Taylor, PC, Blanco, R
Format:	Journal article
Idioma:	English
Publicat:	Elsevier 2022

Ítems similars

Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study
per: Roy Fleischmann, et al.
Publicat: (2024-07-01)

CFTR Rescue in Intestinal Organoids with GLPG/ABBV-2737, ABBV/GLPG-2222 and ABBV/GLPG-2451 Triple Therapy
per: Eyleen de Poel, et al.
Publicat: (2021-09-01)

PB2224: ABBV-744 ALONE OR IN COMBINATION WITH RUXOLITINIB OR NAVITOCLAX IN PATIENTS WITH MYELOFIBROSIS: A PHASE 1B STUDY
per: John Mascarenhas, et al.
Publicat: (2023-08-01)

Impact of upadacitinib or adalimumab as initial therapy on the achievement of 48-week treatment goals in patients with rheumatoid arthritis and inadequate response to methotrexate: Post hoc analysis of a phase 3 study
per: Mysler, E, et al.
Publicat: (2021)

The American Thoracic Society’s Spirometric Criteria Alone is Inadequate in Asthma Diagnosis
per: John A Gjevre, et al.
Publicat: (2006-01-01)

In vivo kinetics of Wolbachia depletion by ABBV-4083 in L. sigmodontis adult worms and microfilariae.
per: Marc P Hübner, et al.
Publicat: (2019-08-01)

Effectiveness of Upadacitinib in Patients with Atopic Dermatitis including those with Inadequate Response to Dupilumab and/or Baricitinib: Results from the BioDay Registry
per: Celeste M. Boesjes, et al.
Publicat: (2023-02-01)

Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
per: Vibeke Strand, et al.
Publicat: (2019-12-01)

Correction to: Upadacitinib improves patient-reported outcomes in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying antirheumatic drugs: results from SELECT-NEXT
per: Vibeke Strand, et al.
Publicat: (2020-06-01)

Construction services welding : examination paper no. 599 /
per: City and Guilds of London Institute
Publicat: ([19-)

Histerectomía laparoscópica en 1 599 pacientes
per: Javier Ernesto Barreras González, et al.

Transcriptome Analysis of Duck and Chicken Brains Infected with Aquatic Bird Bornavirus-1 (ABBV-1)
per: Phuc H. Pham, et al.
Publicat: (2022-10-01)

Upadacitinib for prurigo nodularis
per: Clara Muntaner-Virgili, MD, et al.
Publicat: (2024-06-01)

Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors
per: Fabrice Barlesi, et al.
Publicat: (2021-02-01)

Effects of upadacitinib on patient-reported outcomes: results from SELECT-BEYOND, a phase 3 randomized trial in patients with rheumatoid arthritis and inadequate responses to biologic disease-modifying antirheumatic drugs
per: Vibeke Strand, et al.
Publicat: (2019-12-01)

Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity.
per: Thomas W von Geldern, et al.
Publicat: (2019-02-01)

Preponderance of the oncogenic V599E and V599K mutations in <it>B-raf </it>kinase domain is enhanced in melanoma cutaneous/subcutaneous metastases
per: Hassanzadeh Judith, et al.
Publicat: (2005-06-01)

Model Informed Dosing Regimen and Phase I Results of the Anti‐PD‐1 Antibody Budigalimab (ABBV‐181)
per: John Powderly, et al.
Publicat: (2021-01-01)

Selective MCL-1 inhibitor ABBV-467 is efficacious in tumor models but is associated with cardiac troponin increases in patients
per: Junichiro Yuda, et al.
Publicat: (2023-10-01)

Upadacitinib for the treatment of psoriatic arthritis
per: Diogo Fonseca, et al.
Publicat: (2023-02-01)

P599: RARE GERMLINE VARIANTS IN ATM INFLUENCE THE PATHOGENESIS OF CLL
per: B. L. Lampson, et al.
Publicat: (2022-06-01)

PB2088: ABBV-383 IN COMBINATION WITH ANTI-CANCER REGIMENS IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA: DOSE ESCALATION AND EXPANSION
per: Cesar Rodriguez Valdes, et al.
Publicat: (2023-08-01)

Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
per: Joseph F Merola, et al.
Publicat: (2021-11-01)

1403-A PTPN2/N1 inhibitor ABBV-CLS-484 unleashes potent anti-tumor immunity
per: Wei Qiu, et al.
Publicat: (2023-11-01)

Effective treatment of alopecia universalis with oral upadacitinib
per: Soundos Youssef, MD, et al.
Publicat: (2023-01-01)

Refractory pityriasis rubra pilaris treated with upadacitinib
per: Eingun James Song, MD, et al.
Publicat: (2023-05-01)

Correction: Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study
Publicat: (2021-12-01)

Treatment of Discoid Lupus Erythematosus with Upadacitinib: A Case Report
per: Hu W, et al.
Publicat: (2023-10-01)

ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19
per: Zeynab Fakhar, et al.
Publicat: (2021-01-01)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
per: Alvin F. Wells, et al.
Publicat: (2019-05-01)

Intolerance of aloneness as a prospective predictor of suicidal ideation during COVID-19
per: Katie C. Lewis, et al.
Publicat: (2023-01-01)

Retreatment with upadacitinib in atopic dermatitis: experience in clinical practice
per: S. Martínez-Fernández, et al.
Publicat: (2023-12-01)

Management outcome(s) in eyes with retinoblastoma previously inadequately treated with systemic chemotherapy alone without focal therapy
per: Yacoub A Yousef, et al.
Publicat: (2017-01-01)

Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE
per: Mysler, E, et al.
Publicat: (2022)

US Patent 7,599,807 Compensating for frequency change in flowmeters
per: Tombs, M
Publicat: (2016)

Construction services welding (no.599) : schedules for the in-course assessment of practical work/
per: City and Guilds of London Institute
Publicat: ([19-)

Unilateral blaschkoid lichen planus successfully treated with upadacitinib
per: Chiara Rosenbaum, DO, MS, et al.
Publicat: (2024-03-01)

Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
Publicat: (2019-06-01)

Case of recalcitrant amyopathic dermatomyositis treated with upadacitinib
per: Albert E. Zhou, MD, PhD, et al.
Publicat: (2024-12-01)

Successful Treatment of Disseminated Granuloma Annulare with Upadacitinib
per: Axel De Greef, et al.
Publicat: (2024-03-01)